2LF6

Solution NMR structure of HopABPph1448_220_320 from Pseudomonas syringae pv. phaseolicola str. 1448A, Midwest Center for Structural Genomics target APC40132.4 and Northeast Structural Genomics Consortium target PsT3A

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HNCO	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
2	3D CBCA(CO)NH	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
3	3D HBHA(CO)NH	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
4	3D HNCA	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
5	3D HCCH-TOCSY	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
6	3D CCH-TOCSY	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
7	3D 1H-15N NOESY	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
8	3D 1H-13C NOESY	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
9	3D 1H-13C NOESY aromatic	1 mM [U-100% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298
10	2D 1H-13C HSQC	0.2 mM [U-7% 13C; U-100% 15N] HopAB1Pph1448_220_320, 10 mM [U-100% 2H] TRIS, 300 mM sodium chloride, 10 uM zinc sulphate, 10 mM [U-100% 2H] DTT, 0.01 % NaN3, 10 mM benzamidine, 1 x inhibitor cocktail	90% H2O/10% D2O	300	7.0	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	600
2	Bruker	AVANCE	800

NMR Refinement
Method	Details	Software
simulated annealing		NMRPipe

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	processing	NMRPipe	2.3	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
2	processing	MDDGUI	1.0	Gutmanas, Arrowsmith
3	data analysis	Sparky	3.95	Goddard
4	chemical shift assignment	FMCGUI	2.4	Lemak, Arrowsmith
5	data analysis	FMCGUI	2.4	Lemak, Arrowsmith
6	chemical shift assignment	FAWN	1.0	Lemak, Arrowsmith
7	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
8	refinement	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
9	nmr structure quality assessment	AutoStructure		Huang, Tejero, Powers and Montelione
10	nmr structure quality assessment	PSVS		Bhattacharya and Montelione

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.